CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 24 enrolled
Drug / intervention
Sulfasalazinedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04205357
NCT04205357Phase 1Completed
CompareCT.gov

Phase I Trial Combining Sulfasalazine and Gamma Knife Radiosurgery for Recurrent Glioblastoma

Haukeland University Hospital·interventional·Posted Dec 19, 2019·Updated Mar 3, 2023

In Brief

A Phase 1 clinical trial evaluating Sulfasalazine for Glioma and 2 related conditions. Completed, enrolled 24 participants across 1 site.

Detailed Summary

This study evaluates the safety associated with the addition of sulfasalazine to stereotactic radiosurgery for recurrent glioblastoma. Sulfasalazine is a potential tumor selective radiosensitizer.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGlioma, Glioblastoma, Recurrent Glioblastoma
CountriesNorway
CollaboratorsNorwegian Cancer Society, Northwell Health, Weill Medical College of Cornell University, University of Bergen, Helse Stavanger HF

Timeline

Phase 1CompletedFinished
2020202120222023202420252026
First PostedDec 19, 2019
Enrollment StartMar 1, 2020
Primary CompletionOct 14, 2022
TodayJul 2, 2026
Enrollment to primary: 2.6 yearsPosted 6.5 years ago

Interventions

Sulfasalazinedrug

Sulfasalazine combined with stereotactic radiosurgery